We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Buy National Vision (EYE) Stock Now
Read MoreHide Full Article
National Vision Holdings, Inc. (EYE - Free Report) has been gaining from increased demand for low-cost eye exams, glasses and contact lenses. The company’s strategy for 2021 looks encouraging. Moreover, the raised 2021 guidance buoys optimism. However, stiff competition and high dependence on vendors remain concerning.
Over the past year, the Zacks Rank #1 (Strong Buy) stock has gained 67.5% compared with 19.3% growth of the industry and a 40.7% rise of the S&P 500.
The renowned provider of budget-friendly eye exams, eyeglasses and contact lenses to low-income consumers aims at making eye care and eyewear reasonable for all Americans. It has a market capitalization of $4.16 billion. The company projects 23% growth for the next five years and expects to maintain strength in its business segments. It surpassed estimates in each of the trailing four quarters, the average surprise being 106.84%.
Let’s delve deeper.
Factors at Play
Comp Growth Holds Potential: In the pre-pandemic stage, National Vision had been continuously witnessing positive comps growth. In the first quarter of 2021, adjustable comparable store sales growth increased 35.8%. Eyeglass World delivered a 48.3% increase and America's Best delivered a 35.3% rise. The Legacy segment saw a nearly 30% comp increase.
Strategies for 2021 Look Promising: National Vision plans to continue executing on core growth initiatives and further invest to strengthen competitive advantages. The company had a strong start with 25 openings in the first quarter and continues to plan to open about 75 stores in 2021. It has a solid pipeline of specific locations to open stores for 2021 and 2022. Moreover, the company will stay focused on investing in television advertising and digital marketing. National Vision’s lab network is well-positioned, with the capacity in place to handle the projected 2021 requirement. The company also remains focused to be a key low-cost provider.
Image Source: Zacks Investment Research
Raised Guidance: We are upbeat about National Vision’s raised 2021 outlook, which is indicative of the bullish trend. Net revenues are expected to be $1.975-$2.025 billion (an improvement from the previously announced $1.93-$1.98 billion).
Adjusted earnings per share estimates have also been raised to $1.07-$1.12 (up from the previously stated 88-93 cents).
Adjusted comparable store sales growth is expected to be 16-19% (up from the previously mentioned 13-16%).
However, National Vision operates in a highly competitive optical retail industry. The companies within the industry compete based on recognition of the brand name, price, convenience, selection, services and product quality.
Moreover, National Vision has ties with a very limited number of suppliers for the majority of its eyeglass frames, eyeglass lenses and contact lenses. Thus, high dependence on a limited number of suppliers exposes it to the concentration of supplier risk.
Estimate Trend
The company has been witnessing a positive estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 21.1% north to $1.09.
The Zacks Consensus Estimate for its second-quarter fiscal 2021 revenues is pegged at $494.7 million, suggesting a 90.3% surge from the year-ago reported number.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
Phibro Animal Health has an estimated long-term earnings growth rate of 11%.
IDEXX Laboratories has a projected long-term earnings growth rate of 20%.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
Image: Shutterstock
Here's Why You Should Buy National Vision (EYE) Stock Now
National Vision Holdings, Inc. (EYE - Free Report) has been gaining from increased demand for low-cost eye exams, glasses and contact lenses. The company’s strategy for 2021 looks encouraging. Moreover, the raised 2021 guidance buoys optimism. However, stiff competition and high dependence on vendors remain concerning.
Over the past year, the Zacks Rank #1 (Strong Buy) stock has gained 67.5% compared with 19.3% growth of the industry and a 40.7% rise of the S&P 500.
The renowned provider of budget-friendly eye exams, eyeglasses and contact lenses to low-income consumers aims at making eye care and eyewear reasonable for all Americans. It has a market capitalization of $4.16 billion. The company projects 23% growth for the next five years and expects to maintain strength in its business segments. It surpassed estimates in each of the trailing four quarters, the average surprise being 106.84%.
Let’s delve deeper.
Factors at Play
Comp Growth Holds Potential: In the pre-pandemic stage, National Vision had been continuously witnessing positive comps growth. In the first quarter of 2021, adjustable comparable store sales growth increased 35.8%. Eyeglass World delivered a 48.3% increase and America's Best delivered a 35.3% rise. The Legacy segment saw a nearly 30% comp increase.
Strategies for 2021 Look Promising: National Vision plans to continue executing on core growth initiatives and further invest to strengthen competitive advantages. The company had a strong start with 25 openings in the first quarter and continues to plan to open about 75 stores in 2021. It has a solid pipeline of specific locations to open stores for 2021 and 2022. Moreover, the company will stay focused on investing in television advertising and digital marketing. National Vision’s lab network is well-positioned, with the capacity in place to handle the projected 2021 requirement. The company also remains focused to be a key low-cost provider.
Raised Guidance: We are upbeat about National Vision’s raised 2021 outlook, which is indicative of the bullish trend. Net revenues are expected to be $1.975-$2.025 billion (an improvement from the previously announced $1.93-$1.98 billion).
Adjusted earnings per share estimates have also been raised to $1.07-$1.12 (up from the previously stated 88-93 cents).
Adjusted comparable store sales growth is expected to be 16-19% (up from the previously mentioned 13-16%).
However, National Vision operates in a highly competitive optical retail industry. The companies within the industry compete based on recognition of the brand name, price, convenience, selection, services and product quality.
Moreover, National Vision has ties with a very limited number of suppliers for the majority of its eyeglass frames, eyeglass lenses and contact lenses. Thus, high dependence on a limited number of suppliers exposes it to the concentration of supplier risk.
Estimate Trend
The company has been witnessing a positive estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 21.1% north to $1.09.
The Zacks Consensus Estimate for its second-quarter fiscal 2021 revenues is pegged at $494.7 million, suggesting a 90.3% surge from the year-ago reported number.
Other Key Picks
A few other top-ranked stocks from the broader medical space are Envista Holdings Corporation (NVST - Free Report) , Inogen, Inc. (INGN - Free Report) and Phibro Animal Health Corporation (PAHC - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank stocks here.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
Phibro Animal Health has an estimated long-term earnings growth rate of 11%.
IDEXX Laboratories has a projected long-term earnings growth rate of 20%.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>